Free Newsletter
Venture group targets tech transfer deals in Texas
Emergent Technologies garnered $27.1 million in venture capital to license biotech research programs from the University of Texas. ETI has been operating in Texas for several years now. It specializes in identifying promising biotech research, licensing the technology and then spawning small start-up companies to advance the work. The company typically makes relatively small investments in each start-up and looks to larger pharma companies to come in and partner with them, providing much of the money necessary to grow the companies. Texas has lagged behind a large number of states that have seen their university research explode in recent years. The University of Florida system, meanwhile, has been one of the most active in the licensing arena.
- here's the report from the Austin American-Statesman
ALSO: A collaborative of scientists from South Florida and Latin America have begun seeking partners to advance their work in genomics. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




